TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death

被引:8
作者
Buciuc, Marina [1 ]
Tosakulwong, Nirubol [2 ]
Machulda, Mary M. [3 ]
Whitwell, Jennifer L. [4 ]
Weigand, Stephen D. [2 ]
Murray, Melissa E. [5 ]
Reichard, R. Ross [6 ]
Parisi, Joseph E. [6 ]
Dickson, Dennis W. [5 ]
Boeve, Bradley F. [1 ]
Knopman, David S. [1 ]
Petersen, Ronald C. [1 ]
Josephs, Keith A. [1 ]
机构
[1] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA
[5] Mayo Clin, Dept Neurosci, Jacksonville, FL USA
[6] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; clinical decline; dementia; neuropsychology; TDP-43; proteinopathy; ALZHEIMERS-DISEASE; TDP-43; PATHOLOGY; NEUROPATHOLOGIC ASSESSMENT; HIPPOCAMPAL ATROPHY; IMPAIRMENT; AGE; AD;
D O I
10.3233/JAD-201166
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Transactive response DNA-binding protein of 43 kDa (TDP-43) is associated with memory impairment and overall cognitive decline. It is unclear how TDP-43 contributes to the rate of clinical decline. Objective: To determine whether cross-sectional and longitudinal cognitive and functional decline are associated with anatomical distribution of TDP-43 in the brain. Methods: Longitudinal clinical-neuropathologic autopsy cohort study of 385 initially cognitively normal/mildly impaired older adults prospectively followed until death. We investigated how TDP-43, amyloid-beta (A beta), tau neurofibrillary tangles (NFT), Lewy body disease (LBD), age, sex, and genetics are associated with clinical scores and rates of their longitudinal decline. Results: Of 385 participants, 260 (68%) had no TDP-43, 32 (8%) had TDP-43 limited to amygdala, and 93 (24%) had TDP-43 in the hippocampus and beyond. Higher TDP-43 and Braak NFT stages independently were associated with faster decline in global cognition, functional performance measured by Clinical Dementia Rating scale, and naming and episodic memory, whereas older age was associated with slower rate of cognitive, psychiatric, and functional decline. Cross-sectionally the following associations were found: higher TDP-43 and Braak NFT - worse performance; higher A beta burden - worse global cognition, more behavioral changes, the latter also with higher LBD; older age - worse naming, lower frequency of behavioral changes; female sex - more impaired naming and better preserved episodic memory. There were no genetic associations. Conclusion: The association of TDP-43 distribution with decline in cognitive and functional performance suggests that TDP-43 is playing a role in the clinical progression to dementia. Further characterization of clinical features associated with TDP-43 can facilitate establishment of antemortem diagnosis.
引用
收藏
页码:683 / 693
页数:11
相关论文
共 46 条
[21]   TDP-43 is a key player in the clinical features associated with Alzheimer's disease [J].
Josephs, Keith A. ;
Whitwell, Jennifer L. ;
Weigand, Stephen D. ;
Murray, Melissa E. ;
Tosakulwong, Nirubol ;
Liesinger, Amanda M. ;
Petrucelli, Leonard ;
Senjem, Matthew L. ;
Knopman, David S. ;
Boeve, Bradley F. ;
Ivnik, Robert J. ;
Smith, Glenn E. ;
Jack, Clifford R., Jr. ;
Parisi, Joseph E. ;
Petersen, Ronald C. ;
Dickson, Dennis W. .
ACTA NEUROPATHOLOGICA, 2014, 127 (06) :811-824
[22]   Staging TDP-43 pathology in Alzheimer's disease [J].
Josephs, Keith A. ;
Murray, Melissa E. ;
Whitwell, Jennifer L. ;
Parisi, Joseph E. ;
Petrucelli, Leonard ;
Jack, Clifford R. ;
Petersen, Ronald C. ;
Dickson, Dennis W. .
ACTA NEUROPATHOLOGICA, 2014, 127 (03) :441-450
[23]  
Kaplan E., 2001, Boston Naming Test, VSecond
[24]  
Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/appi.neuropsych.12.2.233
[25]  
Kreutzer J. S., 2011, Encyclopedia of Clinical Neuropsychology, DOI 10.1007/978-0-387-79948-3_1162
[26]   Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort [J].
Latimer, Caitlin S. ;
Burke, Bridget T. ;
Liachko, Nicole F. ;
Currey, Heather N. ;
Kilgore, Mitchell D. ;
Gibbons, Laura E. ;
Henriksen, Jonathan ;
Darvas, Martin ;
Domoto-Reilly, Kimiko ;
Jayadev, Suman ;
Grabowski, Tom J. ;
Crane, Paul K. ;
Larson, Eric B. ;
Kraemer, Brian C. ;
Bird, Thomas D. ;
Keene, C. Dirk .
ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2019, 7 (1) :91
[27]   Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer's disease [J].
Liu, Kathy Y. ;
Reeves, Suzanne ;
McAleese, Kirsty E. ;
Attems, Johannes ;
Francis, Paul ;
Thomas, Alan ;
Howard, Robert .
BRAIN, 2020, 143 :3842-3849
[28]   Concomitant LATE-NC in Alzheimer's disease is not associated with increased tau or amyloid-β pathological burden [J].
McAleese, K. E. ;
Walker, L. ;
Erskine, D. ;
Johnson, M. ;
Koss, D. ;
Thomas, A. J. ;
Attems, J. .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2020, 46 (07) :722-734
[29]   THE CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMERS-DISEASE (CERAD) .2. STANDARDIZATION OF THE NEUROPATHOLOGIC ASSESSMENT OF ALZHEIMERS-DISEASE [J].
MIRRA, SS ;
HEYMAN, A ;
MCKEEL, D ;
SUMI, SM ;
CRAIN, BJ ;
BROWNLEE, LM ;
VOGEL, FS ;
HUGHES, JP ;
VANBELLE, G ;
BERG, L .
NEUROLOGY, 1991, 41 (04) :479-486
[30]   TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD [J].
Nag, Sukriti ;
Yu, Lei ;
Wilson, Robert S. ;
Chen, Er-Yun ;
Bennett, David A. ;
Schneider, Julie A. .
NEUROLOGY, 2017, 88 (07) :653-660